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Standard treatment for clinical stage I esophageal cancer with submucosal invasion (T1b)
has been surgical resection. We conducted a Phase II trial to evaluate the efﬁcacy and the
safety of combined treatment of endoscopic mucosal resection (EMR) and chemoradiother-
apy for clinical stage I (T1b) esophageal cancer. Patients diagnosed as having clinical stage I
(T1b) esophageal cancer which is considered to be resectable by EMR are eligible. When
pathological examination of the EMR specimen conﬁrms T1b tumor with negative or positive
resection margin, the patient undergoes chemoradiotherapy. The study continues until 82
patients with T1b tumor with negative resection margin are enrolled from 20 institutions. The
primary endpoint is 3-year overall survival (OS) in pT1b cases with negative resection margin.
The secondary endpoints are 3-year OS and progression-free survival in all eligible cases,
OS in pT1a-MM cases with margin-negative, complications of EMR and adverse events of
chemoradiotherapy. The data from this trial will be expected to provide a non-surgical
treatment option to the patients with clinical stage I (T1b) esophageal cancer.
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INTRODUCTION
According to the Japanese Classiﬁcation of Esophageal
Cancer by the Japan Esophageal Society, T1 esophageal
tumors deﬁned by the TNM system (6th edition) is further
divided into T1a (mucosal) and T1b (submucosal) tumors by
the Japanese Classiﬁcation of Esophageal Cancer (1).
Endoscopic mucosal resection (EMR) is usually indicated
for T1a tumor, whereas the standard treatment for T1b
tumors has been a surgical resection with adequate lymph
node dissection in Japan because of the high incidence of
lymph node metastasis (40%) (2). However, surgical
resection often deteriorates patient’s general condition. Some
patients with clinical T1b esophageal cancer are over-treated
by surgery with a result of pathological T1a tumor, because
the accuracy of diagnosis of T1b esophageal cancer is not
high.
Recent advance in techniques of EMR including endo-
scopic submucosal dissection (ESD) enables us to remove
the clinical T1b tumor and gives us accurate diagnosis of
depth of invasion. However, the patients with T1b are at risk
of lymph node metastasis (3) and therefore EMR alone
cannot be considered as curative.
Chemoradiotherapy is one of the effective modalities for
both early and advanced esophageal tumors. Since chemora-
diotherapy is less toxic than surgical resection, the useful-
ness has been tested in several clinical trials (4,5). In Japan,
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efﬁcacy and the safety of concurrent chemoradiotherapy
using 5-ﬂuoraouracil (5-FU) plus cisplatin (CDDP) for T1
tumors (6). However, 22% of patients showed minor relapses
that needed to be removed by endoscopic treatment. We
have therefore conducted a pilot study of EMR followed by
chemoradiotherapy and have reported promising results (7).
Thus, the Japan Clinical Oncology Group initiated this
multi-institutional Phase II trial (JCOG0508) to evaluate the
efﬁcacy and the safety of combined treatment of EMR and
chemoradiotherapy for clinical stage I (cT1bN0) esophageal
cancer.
The Protocol Review Committee of JCOG approved the
protocol in October 2006 and the study was activated in
December 2006.
JCOG0508 PROTOCOL
PURPOSE
The aim of this study is to evaluate the efﬁcacy and the safety
of combined treatment of EMR and chemoradiotherapy for
clinical stage I (T1b) esophageal cancer.
STUDY SETTING
The study is a multi-institutional (20 centers), single-arm
Phase II trial.
RESOURCES
This study is supported by the Grants-in-Aid for Cancer
Research (17S-3, 17S-5, 20S-3, 20S-6) and Health and
Labour Sciences Research Grant for Clinical Cancer
Research (17-12) from the Ministry of Health, Labour and
Welfare, Japan.
ENDPOINTS
The primary endpoint is 3-year overall survival (OS) in
pT1b cases with negative resection margin (comment 4).
The secondary endpoints are 3-year OS and progression-free
survival (PFS) in all eligible cases, OS in pT1a-MM
(muscularis mucosa) cases with negative resection
margin, complications of EMR and adverse events of
chemoradiotherapy.
In this trial, resection margin is diagnosed from
endoscopic ﬁndings immediately after mucosal resection for
horizontal margin and from pathological ﬁndings for vertical
margin. OS is deﬁned as the time from registration to death
from any cause, and it is censored at the last contact day for
living patient. PFS is deﬁned as the time from registration to
either the ﬁrst event of progression or death from any cause,
and it is censored at the latest day when patient is alive
without progression.
INCLUSION CRITERIA
Patients are included in this trial if they meet all of the fol-
lowing criteria: (i) histologically proven squamous cell carci-
noma of the esophagus by endoscopic biopsy, (ii) tumors
located within the thoracic esophagus, (iii) depth of tumor
invasion is diagnosed as T1b by endoscopy and endoscopic
ultrasonography, (iv) the number of multiple
intra-esophageal tumors is less than three, and the depths of
invasion of them are diagnosed as cT1a-EP (carcinoma
in situ) or cT1a-LPM (tumor invades lamina propria
mucosa), (v) clinically node-negative (cN0) and no metasta-
sis to other organs (cM0), (vi) size of main tumor is 5c m ,
and circularity of esophageal lumen is less than three-
fourths, (vii) no ulcerative lesion in the tumors, (viii) no
intra-esophageal metastasis, (ix) no prior treatment of che-
motherapy or radiation therapy against any other malignan-
cies, except for previous curative EMR for pT1 esophageal
cancer, (x) aged between 20 and 75 years old, (xi) perform-
ance status of 0 or 1, (xii) sufﬁcient organ functions and
(xiii) written informed consent.
EXCLUSION CRITERIA
Patients are excluded if they meet any of the following
criteria: (i) iodine allergy, (ii) enable to discontinue anticoa-
gulant or antiplatelet medications, (iii) synchronous or meta-
chronous (within 5 years) malignancy other than carcinoma
in situ, (iv) pregnant or breast-feeding women, (v) severe
mental disease, (vi) systemic administration of corticoster-
oids, (vii) HBs antigen positive, (viii) active bacterial or
fungous infection, (ix) concurrent unstable angina or myo-
cardial infarction within 3 months before registration, (x)
unstable hypertension, (xi) diabetes mellitus, uncontrolled or
controlled with insulin, or (xii) interstitial pneumonia, lung
ﬁbrosis or severe emphysema.
REGISTRATION
After conﬁrming the inclusion/exclusion criteria by
telephoning or faxing the JCOG Data Center, the patients are
registered into this JCOG0508 trial.
QUALITY CONTROL OF EMR
Twenty institutions among the Gastrointestinal Oncology
Study Group of the JCOG participate in this trial. All partici-
pating physicians have agreed to the technical details for
EMR. For quality control of EMR technique and endoscopic
diagnosis, we perform central review of the photographs in
all patients at the semi-annual investigators meeting.
Regarding an ESD procedure, we permit it only for expert
physicians who have signiﬁcant experiences in ESD and
EMR, and they are registered by the primary investigator
(M.M.). The minimum request for ESD permission is the
experience of EMR  50 and ESD  10 for esophageal
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2% in total.
TREATMENT METHODS
ENDOSCOPIC MUCOSAL RESECTION
EMR is performed against esophageal tumors within 30 days
from registration. The technical methods of EMR approved
in this trial are a two-channel method, a cap method or an
esophageal endoscopic mucosal resection-tube method (8).
Only the registered physicians are allowed to perform ESD
in this trial. After EMR, it should be conﬁrmed endoscopi-
cally that no iodine-unstained area is left. Physicians need to
take pictures before and after EMR and submit them to the
primary investigator for quality control of EMR technique
and endoscopic diagnosis.
CHEMORADIOTHERAPY
In cases of pT1a tumor with negative resection margin and
no vascular invasion, no additional treatment after EMR is
given. In other cases, chemoradiotherapy was started at
29–70 days after EMR. The chemotherapy regimen is con-
tinuous 5-FU (700 mg/m
2/day, days 1–4 and 29–32) and
CDDP (70 mg/m
2/day, days 1 and 29). The dose of radio-
therapy is 41.4 Gy/23 Fr/5 weeks (5 days/week) for cases
with negative resection margin and 50.4 Gy/28 Fr/5 weeks
(5 days/week) with boost on the primary site for the case
with positive resection margin, respectively.
FOLLOW-UP
Patients are followed with blood tests, upper gastrointestinal
endoscopy and computed tomography at least every
4 months for 3 years.
STUDY DESIGN AND STATISTICAL METHODS
This trial determines the efﬁcacy and the safety of combined
treatment of EMR and chemoradiotherapy for cT1b esopha-
geal cancer in terms of 3-year OS. Additionally, 3-year OS
in all eligible patients are evaluated as the most important
secondary endpoint. The sample size is 82 for pT1b cases
with negative resection margin with the power of 90%. In
case this hypothesis rejected, the secondary hypothesis for
all eligible patients can be tested using hierarchical method
keeping trial-wise a error nominal level, one-sided 5%, with
the power of 80%. To test the hypothesis, 3-year OS esti-
mated by Kaplan–Meier method and its conﬁdence interval
by Greenwood’s formula is used. The total number of regis-
tered patients is estimated as 137, because the proportion of
pT1b cases with margin-negative among all eligible patients
is predicted as 60%.
This study was registered with UMIN-CTR [www.umin.
ac.jp/ctr/], identiﬁcation number UMIN000000553.
INTERIM ANALYSIS AND MONITORING
Interim analysis is not planned. If the number of cases with
treatment-related death, severe (Grade 4) bleeding or severe
(Grade 4) perforation reaches seven, the registration will be
suspended unless the JCOG Data and Safety Monitoring
Committee approves to continue this trial. The JCOG Data
Center is responsible for data management, central monitor-
ing and statistical analysis. This center also provides semi-
annual monitoring reports, each of which is submitted to and
reviewed by the JCOG Data and Safety Monitoring
C o m m i t t e eo nd e m a n do ft h eJ C O GD a t aC e n t e r .N o n eo f
physicians administering the interventions are involved in
the data analysis. For quality assurance, site-visit audits, not
for a speciﬁc study basis but for the study group basis, are
done by the JCOG Audit Committee.
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The initially participating hospitals are as follows: Iwate
Prefectural Central Hospital, Ibaragi Prefectural Central
Hospital, Tochigi Cancer Center Hospital, National Cancer
Center Hospital East, National Cancer Center Hospital,
Tokyo Metropolitan Cancer and Infectious diseases Center
Komagome Hospital, Showa University Hospital, Cancer
Institute Ariake Hospital, Kitasato University East Hospital,
Kanagawa Cancer Center Hospital, Ishikawa Prefectural
Central Hospital, Saku Central Hospital, Shizuoka Cancer
Center Hospital, Aichi Cancer Center Central Hospital,
Kyoto University Hospital, Osaka Medical Center for
Cancer and Cardiovascular Disease, Osaka City Medical
Center, and Osaka Medical College Hospital.
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